• Third PAT-SM6 patent has been granted in United States, that provides protection through to November 2024
• Patent covers method of treatment for various cancers including a broad set of proliferative disorders

Melbourne, Australia; 18 June, 2014: Patrys Limited (ASX: PAB), a clinical stage biotechnology company is pleased to advise that it has been granted a third United States patent for clinical anti-cancer product PAT-SM6.

The United States Patent Office has issued the official “Letters Patent” on a key patent in the PAT-SM6 family; application number US 8,741,296 entitled “Adenocarcinoma specific antibody SAM-6, and uses thereof”. This is the third patent to be granted in the United States.

This patent is one of a series of patent applications that have been submitted to cover the PAT-SM6 product, target and mechanism of action. The claims in this patent cover method of treatment for various cancers including a broad set of proliferative disorders.

Previously in February 2012, Patrys was granted a patent by the United States Patent Office that contains claims covering the mechanism of action of PAT-SM6. In November 2013, Patrys was also granted an Australian patent with claims that cover methods of use of PAT-SM6 for the treatment of various cancers including multiple myeloma.

“This new patent goes a step further in protection for our lead antibody PAT-SM6 and is in line with Patrys’ intellectual property strategy to pursue multiple filings to enable broad multi-layered protection”, said Dr. Marie Roskrow, Patrys’ CEO.

Patrys' lead antibody drug PAT-SM6 has recently completed a Phase I/IIa clinical trial in patients with relapsed and refractory multiple myeloma, with 4/12 patients (33%) showing evidence of stable disease. Patrys is now preparing to commence a follow-up trial using PAT-SM6 in combination with Amgen’s Carfilzomib.

To date, eight patents in the PAT-SM6 family have been granted in various jurisdictions including Europe, Japan, the US and Australia; with additional patents pending in Canada, Europe and the United States.

About Patrys Limited:
Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of natural human antibodies as therapies for cancer and other major diseases. Patrys has a deep pipeline of anti-cancer natural human antibodies that enable both internal development and partnering opportunities. More information can be found at www.patrys.com

About PAT-SM6:
PAT-SM6 is a natural human IgM antibody which has been shown to have potent anti-cancer properties in a large number of laboratory and animal studies. More specifically, Patrys has screened PAT-SM6 against more than 200 tumours from individual patients with various cancers, and the product binds to over 90% of the tumours screened regardless of cancer type, patient age, gender or disease stage. Patrys has filed patent applications to cover the PAT-SM6 antibody molecule, disease target and the mechanism of action. Patrys’ PAT-SM6 has shown convincing evidence of potential therapeutic benefit in the recently completed Phase I/IIa clinical trial in patients with relapsed and refractory multiple myeloma. PAT-SM6 has been granted orphan drug status in Europe and the USA for multiple myeloma. Patrys has also successfully completed a Phase I clinical trial to evaluate PAT-SM6 as a therapy for melanoma. Patrys is now preparing for the next clinical trial (a combination study of PAT-SM6 and Carfilzomib) which is to be sponsored by Onyx Pharmaceuticals, a subsidiary of Amgen.

About Multiple Myeloma:
Multiple myeloma is a type of bone marrow cancer arising from plasma cells, and new therapies are desperately needed to treat patients who become resistant to established chemotherapeutics. There is an estimated 220,000 cases worldwide and the incidence is increasing. The five-year survival of patients is approximately 30% (at 10 years ~20%). Despite new marketed therapies, multiple myeloma remains largely incurable and fatal. The multiple myeloma market is dominated by three major products: Revlimid, Velcade and Kyprolis (Carfilzomib) with combined net sales greater than US$8 Billion in 2013.